Chugai Pharmaceutical Co., Ltd. (CHGCY)

Market Cap	93.21B
Revenue (ttm)	8.16B
Net Income (ttm)	2.74B
Shares Out	n/a
EPS (ttm)	1.66
PE Ratio	34.03
Forward PE	n/a
Dividend	1.22 (4.26%)
Ex-Dividend Date	Jun 27, 2025

Volume	2,892
Average Volume	164,264
Open	28.88
Previous Close	29.43
Day's Range	28.61 - 29.40
52-Week Range	14.52 - 31.26
Beta	0.70
RSI	60.60
Earnings Date	Apr 24, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,026
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCY

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in JPY